{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T23:03:24Z","timestamp":1776207804832,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2020-I2M-C&T-B-087"],"award-info":[{"award-number":["2020-I2M-C&T-B-087"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2021YFE0106900"],"award-info":[{"award-number":["2021YFE0106900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s12185-022-03402-z","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T10:16:46Z","timestamp":1658139406000},"page":"669-677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Droplet digital PCR for genetic mutations monitoring predicts relapse risk in pediatric acute myeloid leukemia"],"prefix":"10.1007","volume":"116","author":[{"given":"Xiaoyan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lipeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meihui","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongzheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixian","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"3402_CR1","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","volume":"33","author":"CM Zwaan","year":"2015","unstructured":"Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015;33:2949\u201362.","journal-title":"J Clin Oncol"},{"key":"3402_CR2","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","volume":"32","author":"M Rasche","year":"2018","unstructured":"Rasche M, Zimmermann M, Borschel L, Bourquin JP, Dworzak M, Klingebiel T, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia. 2018;32:2167\u201377.","journal-title":"Leukemia"},{"key":"3402_CR3","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","volume":"120","author":"MR Loken","year":"2012","unstructured":"Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children\u2019s Oncology Group. Blood. 2012;120:1581\u20138.","journal-title":"Blood"},{"key":"3402_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fped.2019.00412","volume":"7","author":"B Buldini","year":"2019","unstructured":"Buldini B, Maurer-Granofszky M, Varotto E, Dworzak MN. Flow-cytometric monitoring of minimal residual disease in pediatric patients with acute myeloid leukemia: recent advances and future strategies. Front Pediatr. 2019;7:412.","journal-title":"Front Pediatr"},{"key":"3402_CR5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"3402_CR6","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079\u201389.","journal-title":"N Engl J Med"},{"key":"3402_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"3402_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/gcc.22806","volume":"58","author":"S Vosberg","year":"2019","unstructured":"Vosberg S, Greif PA. Clonal evolution of acute myeloid leukemia from diagnosis to relapse. Genes Chromosomes Cancer. 2019;58:839\u201349.","journal-title":"Genes Chromosomes Cancer"},{"key":"3402_CR9","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132:1703\u201313.","journal-title":"Blood"},{"key":"3402_CR10","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/s41375-018-0298-3","volume":"33","author":"V Alfonso","year":"2019","unstructured":"Alfonso V, Iaccarino L, Ottone T, Cicconi L, Lavorgna S, Divona M, et al. Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia. Leukemia. 2019;33:1527\u201330.","journal-title":"Leukemia"},{"key":"3402_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41375-020-0817-x","volume":"35","author":"M Wakamatsu","year":"2021","unstructured":"Wakamatsu M, Okuno Y, Murakami N, Miwata S, Kitazawa H, Narita K, et al. Detection of subclonal SETBP1 and JAK3 mutations in juvenile myelomonocytic leukemia using droplet digital PCR. Leukemia. 2021;35:259\u201363.","journal-title":"Leukemia"},{"key":"3402_CR12","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1111\/bjh.16442","volume":"189","author":"R Frazzi","year":"2020","unstructured":"Frazzi R, Bizzarri V, Albertazzi L, Cusenza VY, Coppolecchia L, Luminari S, et al. Droplet digital PCR is a sensitive tool for the detection of TP53 deletions and point mutations in chronic lymphocytic leukaemia. Br J Haematol. 2020;189:e49\u201352.","journal-title":"Br J Haematol"},{"key":"3402_CR13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275\u201391.","journal-title":"Blood"},{"key":"3402_CR14","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"3402_CR15","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"3402_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2018","unstructured":"Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103\u201312.","journal-title":"Nat Med"},{"key":"3402_CR17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/bjh.14247","volume":"175","author":"N Shiba","year":"2016","unstructured":"Shiba N, Yoshida K, Shiraishi Y, Okuno Y, Yamato G, Hara Y, et al. Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia. Br J Haematol. 2016;175:476\u201389.","journal-title":"Br J Haematol"},{"key":"3402_CR18","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1097\/HS9.0000000000000031","volume":"2","author":"A Marceau-Renaut","year":"2018","unstructured":"Marceau-Renaut A, Duployez N, Ducourneau B, Labopin M, Petit A, Rousseau A, et al. Molecular profiling defines distinct prognostic subgroups in childhood AML: a report from the French ELAM02 study group. Hemasphere. 2018;2:e31.","journal-title":"Hemasphere"},{"key":"3402_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41417-019-0133-7","volume":"27","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Wang F, Chen X, Zhang Y, Wang M, Liu H, et al. Companion gene mutations and their clinical significance in AML with double mutant CEBPA. Cancer Gene Ther. 2020;27:599\u2013606.","journal-title":"Cancer Gene Ther"},{"key":"3402_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.106223","volume":"86","author":"R Marcolin","year":"2019","unstructured":"Marcolin R, Guolo F, Minetto P, Clavio M, Manconi L, Ballerini F, et al. A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia. Leuk Res. 2019;86: 106223.","journal-title":"Leuk Res"},{"key":"3402_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/leu.2016.364","volume":"31","author":"HP Koeffler","year":"2017","unstructured":"Koeffler HP, Leong G. Preleukemia: one name, many meanings. Leukemia. 2017;31:534\u201342.","journal-title":"Leukemia"},{"key":"3402_CR22","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s00277-017-3161-0","volume":"96","author":"S Nassereddine","year":"2017","unstructured":"Nassereddine S, Lap CJ, Haroun F, Tabbara I. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia. Ann Hematol. 2017;96:1983\u201391.","journal-title":"Ann Hematol"},{"key":"3402_CR23","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1038\/leu.2015.121","volume":"29","author":"M Tokumasu","year":"2015","unstructured":"Tokumasu M, Murata C, Shimada A, Ohki K, Hayashi Y, Saito AM, et al. Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia\/Lymphoma Study Group AML-05 trial. Leukemia. 2015;29:2438\u201341.","journal-title":"Leukemia"},{"key":"3402_CR24","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1182\/blood-2014-03-563403","volume":"124","author":"Y Wang","year":"2014","unstructured":"Wang Y, Wu DP, Liu QF, Qin YZ, Wang JB, Xu LP, et al. In adults with t(8;21)AML, posttransplant RUNX1\/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood. 2014;124:1880\u20136.","journal-title":"Blood"},{"key":"3402_CR25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2015-10-677021","volume":"127","author":"TN Wong","year":"2016","unstructured":"Wong TN, Miller CA, Klco JM, Petti A, Demeter R, Helton NM, et al. Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood. 2016;127:893\u20137.","journal-title":"Blood"},{"key":"3402_CR26","doi-asserted-by":"publisher","first-page":"12152","DOI":"10.1038\/s41598-020-69194-6","volume":"10","author":"S Wang","year":"2020","unstructured":"Wang S, Wu Z, Li T, Li Y, Wang W, Hao Q, et al. Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia. Sci Rep. 2020;10:12152.","journal-title":"Sci Rep"},{"issue":"9","key":"3402_CR27","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3390\/ijms20092249","volume":"20","author":"D Cilloni","year":"2019","unstructured":"Cilloni D, Petiti J, Rosso V, Andreani G, Dragani M, Fava C, et al. Digital PCR in myeloid malignancies: ready to replace quantitative PCR? Int J Mol Sci. 2019;20(9):2249.","journal-title":"Int J Mol Sci"},{"key":"3402_CR28","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.3390\/cancers12071738","volume":"12","author":"S Grassi","year":"2020","unstructured":"Grassi S, Guerrini F, Ciabatti E, Puccetti R, Salehzadeh S, Metelli MR, et al. Digital droplet PCR is a specific and sensitive tool for detecting IDH2 mutations in acute myeloid leukemia patients. Cancers (Basel). 2020;12:1738.","journal-title":"Cancers (Basel)"},{"key":"3402_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.leukres.2018.04.013","volume":"69","author":"Y Tan","year":"2018","unstructured":"Tan Y, Liu Z, Wang W, Zhu G, Guo J, Chen X, et al. Monitoring of clonal evolution of double C-KIT exon 17 mutations by droplet digital PCR in patients with core-binding factor acute myeloid leukemia. Leuk Res. 2018;69:89\u201393.","journal-title":"Leuk Res"},{"key":"3402_CR30","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jmoldx.2017.03.005","volume":"19","author":"N Mencia-Trinchant","year":"2017","unstructured":"Mencia-Trinchant N, Hu Y, Alas MA, Ali F, Wouters BJ, Lee S, et al. Minimal residual disease monitoring of acute myeloid leukemia by massively multiplex digital PCR in patients with NPM1 mutations. J Mol Diagn. 2017;19:537\u201348.","journal-title":"J Mol Diagn"},{"key":"3402_CR31","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1182\/bloodadvances.2018016378","volume":"2","author":"F Ravandi","year":"2018","unstructured":"Ravandi F, Walter RB, Freeman SD. Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv. 2018;2:1356\u201366.","journal-title":"Blood Adv"},{"key":"3402_CR32","doi-asserted-by":"publisher","first-page":"56746","DOI":"10.18632\/oncotarget.10778","volume":"7","author":"R Masetti","year":"2016","unstructured":"Masetti R, Castelli I, Astolfi A, Bertuccio SN, Indio V, Togni M, et al. Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing. Oncotarget. 2016;7:56746\u201357.","journal-title":"Oncotarget"},{"key":"3402_CR33","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41375-018-0034-z","volume":"32","author":"M Rothenberg-Thurley","year":"2018","unstructured":"Rothenberg-Thurley M, Amler S, Goerlich D, Kohnke T, Konstandin NP, Schneider S, et al. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia. 2018;32:1598\u2013608.","journal-title":"Leukemia"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03402-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03402-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03402-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T01:20:56Z","timestamp":1666574456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03402-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["3402"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03402-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]},"assertion":[{"value":"1 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was obtained from the Ethics Committee and Institutional Review Board of Chinese Academy of Medical Sciences and Peking Union Medical College.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}